These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 4522079)

  • 1. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Observations on antibody reaction scores on individual patients.
    O'Mahony MG
    Scand J Respir Dis Suppl; 1973; 84():64-72. PubMed ID: 4522079
    [No Abstract]   [Full Text] [Related]  

  • 2. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. The detection of rifampicin-dependent antibodies.
    Worlledge S
    Scand J Respir Dis Suppl; 1973; 84():60-3. PubMed ID: 4544603
    [No Abstract]   [Full Text] [Related]  

  • 3. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Correlation between the presence of rifampicin-dependent antibodies and the clinical data.
    Worlledge S
    Scand J Respir Dis Suppl; 1973; 84():125-8. PubMed ID: 4522065
    [No Abstract]   [Full Text] [Related]  

  • 4. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.
    Girling DJ
    Scand J Respir Dis Suppl; 1973; 84():119-24. PubMed ID: 4522064
    [No Abstract]   [Full Text] [Related]  

  • 5. Proceedings of the Workshop on Intermittent Drug Therapy and Immunological Implications in Antituberculous Treatment with Rifampicin. Oct. 2-3, 1972 Stockholm. Organized by The Department of Thoracic Medicine, Karolinska Sjukhuset.
    Scand J Respir Dis Suppl; 1973; 84():1-193. PubMed ID: 4593267
    [No Abstract]   [Full Text] [Related]  

  • 6. A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy. A Hong Kong Tuberculosis Treatment Services-British Medical Research Council Investigation.
    Clin Allergy; 1974 Mar; 4(1):1-12. PubMed ID: 4824569
    [No Abstract]   [Full Text] [Related]  

  • 7. Rifampicin-dependent antibodies during intermittent treatment.
    Virgilio R
    Scand J Respir Dis Suppl; 1973; 84():83-6. PubMed ID: 4593269
    [No Abstract]   [Full Text] [Related]  

  • 8. Observations on the influence of rifampicin on the immune system.
    Arioli V; Bassi L; Di Berardino L; Silvestri LG
    Scand J Respir Dis Suppl; 1973; 84():20-2. PubMed ID: 4593268
    [No Abstract]   [Full Text] [Related]  

  • 9. [Daily and intermittent regimens using ethambutol and rifampicin in the treatment of unresponsive cases. (Evaluation after 1 year.) II. Side effects].
    Girling DJ
    Bull Int Union Tuberc; 1974; 49(1):451-5. PubMed ID: 4619567
    [No Abstract]   [Full Text] [Related]  

  • 10. Controlled clinical evaluation of three intermittent regimens employing low-dosage schedules of rifampicin in original treatment of pulmonary tuberculosis. Preliminary data on effectiveness and side effects.
    Nitti V
    Scand J Respir Dis Suppl; 1973; 84():180-5. PubMed ID: 4593266
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of rifampicin on the nonspecific reactivity and natural resistence to tuberculosis in guinea pigs].
    Shiniberov VA
    Probl Tuberk; 1979 Jan; (1):50-4. PubMed ID: 419108
    [No Abstract]   [Full Text] [Related]  

  • 12. [Conditioned reflex regulation of the immune response].
    Ader R
    Fiziol Cheloveka; 1984; 10(2):211-20. PubMed ID: 6335877
    [No Abstract]   [Full Text] [Related]  

  • 13. A study of rifampicin antigenic site.
    Homberg JC; Pujet JC; Salmon C
    Scand J Respir Dis Suppl; 1973; 84():36-9. PubMed ID: 4544601
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunosuppressive therapy using cytostatics].
    Schumacher K; Ricken D
    Internist (Berl); 1971; 12():Suppl 1:142-8. PubMed ID: 4944100
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of tuberculostatic activity and blood concentration of new agents--rifampicin and ethambutol--in patients with pulmonary tuberculosis].
    Mkrtchian SV; Ushkin VV
    Antibiotiki; 1971 May; 16(5):472-7. PubMed ID: 5002224
    [No Abstract]   [Full Text] [Related]  

  • 16. [Daily and intermittent regimens using ethambutol and rifampicin in the treatment of unresponsive cases. (Evaluation after 1 year.) I. Clinical course].
    Horsfall PA
    Bull Int Union Tuberc; 1974; 49(1):447-51. PubMed ID: 4619566
    [No Abstract]   [Full Text] [Related]  

  • 17. Haematological changes during intermittent treatment with rifampicin.
    Wislawska-Orlowska B; Pniewski T
    Scand J Respir Dis Suppl; 1973; 84():94-7. PubMed ID: 4522080
    [No Abstract]   [Full Text] [Related]  

  • 18. Rifampicin-dependent antibodies in twice-weekly treated patients.
    Algeorge G; Rudescu D; Alexandrescu D
    Scand J Respir Dis Suppl; 1973; 84():98-101. PubMed ID: 4522081
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse reactions during rifampicin treatment.
    Riska N; Mattson K
    Scand J Respir Dis; 1972; 53(2):87-96. PubMed ID: 5052728
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunosuppressive drugs.
    Makinodan T; Santos GW; Quinn RP
    Pharmacol Rev; 1970 Jun; 22(2):189-247. PubMed ID: 4914001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.